Propanc Biopharma, Inc. announced that a certificate of grant for the company?s ?composition of proenzymes for cancer treatment,? patent was received from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes (trypsinogen and chymotrypsinogen) contained in the PRP formulation.

This is the fourth European patent granted and after validation in selected countries across Europe, will result in the Company?s IP portfolio growing to 94 patents filed in major global jurisdictions. This PRP dosing patent is an important part of the IP portfolio as it covers possible future clinical dosage ranges for PRP as the Company advances into early-stage clinical development. Furthermore, Europe is considered a major global region which accounted for 23.4% of global pharmaceutical sales in 2021, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).